Altered Expression of Type-1 and Type-2 Cannabinoid Receptors in Celiac Disease

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Battista, Natalia ^a,b   Di Sabatino, Antonio ^c   Di Tommaso, Monia ^a   Biancheri, Paolo ^c   Rapino, Cinzia ^a   Giuffrida, Paolo ^c   Papadia, Cinzia ^d   Montana, Chiara ^d   Pasini, Alessandra ^c   Vanoli, Alessandro ^c   Lanzarotto, Francesco ^e   Villanacci, Vincenzo ^e   Corazza, Gino R ^c   Maccarrone, Mauro ^b,f  

^a UNIVERSITY OF TERAMO   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

^e Spedali Civili di Brescia ^*  (Italy)

^f UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; MESSENGER RNA;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CANNABINOID 1 RECEPTOR GENE; CANNABINOID 2 RECEPTOR GENE; CELIAC DISEASE; CONTROLLED STUDY; DISEASE COURSE; EX VIVO STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING;

ADULT; CELIAC DISEASE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GLIADIN; HUMANS; INTESTINAL MUCOSA; MALE; MICROSCOPY, CONFOCAL; PROTEIN BINDING; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER;

EID: 84876428093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062078     Document Type: Article

References (31)

1. Basavaraji B (2011) Receptors for cannabinoids. How marihuana triggers its effects. In: Murillo Rodríguez E, editor. Molecular, biochemical and genetic aspects of cannabinoids. Mérida: Universidad Anahuác Mayab; pp. 88-113.
2. Battista N, Bari M, Di Tommaso M, Maccarrone M, (2012) The endocannabinoid system: an overview. Frontiers in Behavioral Neuroscience 6: 1-7.
3. Howlett AC, Blume LC, Dalton GD, (2010) CB1 cannabinoid receptors and their associated proteins. Curr Med Chem 17: 1382-1393.
4. Pertwee RG, (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17: 1360-1381.
5. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332.
6. den Boon FS, Chameau P, Schaafsma-Zhao Q, van Aken W, Bari M, et al. (2012) Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci U S A 109: 3534-3539.
7. Wong BS, Camilleri M, Eckert D, Carlson P, Ryks M, et al. (2012) Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil 24: 358-e169.
8. Proto MC, Gazzerro P, Di Croce L, Santoro A, Malfitano AM, et al. (2012) Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J Cell Physiol 227: 250-258.
9. Di Sabatino A, Battista N, Biancheri P, Rapino C, Rovedatti L, et al. (2011) The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol 4: 574-583.
10. Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, et al. (2011) Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 141: 1638-1647.
11. D'Argenio G, Petrosino S, Gianfrani C, Valenti M, Scaglione G, et al. (2007) Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med 85: 523-530.
12. Battista N, Di Sabatino A, Di Tommaso M, Biancheri P, Rapino C, et al. (2012) Abnormal anandamide metabolism in celiac disease. J Nutr Biochem 23: 1245-1248.
13. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, et al. (2006) Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20: 568-570.
14. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Bátkai S, et al. (2008) Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 7: 227-235.
15. Rossi F, Bellini G, Tolone C, Luongo L, Mancusi S, et al. (2012) The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. Pharmacol Res 66: 88-94.
16. Di Sabatino A, Pickard KM, Gordon JN, Salvati V, Mazzarella G, et al. (2007) Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology 133: 1175-1187.
17. Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, et al. (2009) Transforming growth factor-β signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 58: 777-789.
18. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
19. Schicho R, Storr M, (2011) Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. Can J Gastroenterol 25: 377-383.
20. Alhouayek M, Muccioli GG (2012) The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med in press.
21. Di Marzo V, Piscitelli F, (2011) Gut feelings about the endocannabinoid system. Neurogastroenterol Motil 23: 391-398.
22. Storr M, Emmerdinger D, Diegelmann J, Pfennig S, Ochsenkühn T, et al. (2010) The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's disease. PLoS ONE 5: e9453.
23. Park JM, Choi MG, Cho YK, Lee IS, Kim SW, et al. (2011) Cannabinoid receptor 1 gene polymorphism and irritable bowel syndrome in the Korean population: a hypothesis-generating study. J Clin Gastroenterol 45: 45-49.
24. Cani PD, (2012) Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue. Clin Microbiol Infect 18: 50-53.
25. Pandey R, Hegde VL, Nagarkatti M, Nagarkatti PS, (2011) Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model. J Pharmacol Exp Ther 338: 819-828.
26. Singh UP, Singh NP, Singh B, Price RL, Nagarkatti M, et al. (2012) Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 258: 256-267.
27. Zurolo E, Iyer AM, Spliet WG, Van Rijen PC, Troost D, et al. (2010) CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies. Neuroscience 170: 28-41.
28. D'Addario C, Di Francesco A, Arosio B, Gussago C, Dell'Osso B, et al. (2012) Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS ONE 7: e39186.
29. Camilleri M, Kolar GJ, Vazquez-Roque MI, Carlson P, Burton DD, et al. (2013) Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits. Am J Physiol Gastrointest Liver Physiol 304: G553-560.
30. Rossi F, Bellini G, Alisi A, Alterio A, Maione S, et al. (2012) Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease. PLoS One 7: e42259.
31. Caruso MG, Gazzerro P, Notarnicola M, Cisternino AM, Guerra V, et al. (2012) Cannabinoid type 1 receptor gene polymorphism and macronutrient intake. J Nutrigenet Nutrigenomics 5: 305-313.